Regado Biosciences Establishes Medical Advisory Board
Basking Ridge, NJ (June 2, 2009) — Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the establishment of its Medical Advisory Board (MAB). Regado’s MAB is comprised of leaders in the fields of cardiology, thrombosis and coagulation, and cardiovascular surgery. These highly regarded leaders will advise the Company on its clinical programs and provide strategic guidance to support the eventual commercialization of Regado’s products, in particular, the Company’s leading product candidate, the REG1 anticoagulation system.
David J. Mazzo, Ph.D., President and Chief Executive Officer of Regado, stated, "We are delighted to announce the formation of our MAB and look forward to the knowledge, guidance and creativity that they will bring to our development programs. We expect that our Medical Advisory Board will be instrumental in the achievement of Regado’s strategic imperatives and considered ourselves privileged to welcome this extremely accomplished group of physicians to our company."
Robert Harrington, MD, Director of the Duke Clinical Research Institute and Chairman of Regado’s Medical Advisory Board, added, "This advisory board comprises talented, respected and objective physician-investigators. Their expertise, judgment and clinical experience will be important to the continued development of the REG1 anticoagulation system and to Regado technology in general. I am honored to chair this renowned group."
Regado’s Medical Advisory Board is comprised of the following members:
About Regado Biosciences, Inc.
Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system is comprised of a nuclease-stabilized RNA aptamer therapeutic that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied initially to acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado’s technology is designed to give physicians the ability to actively and directly control each system’s therapeutic effect providing a safe and unique approach to personalized medicine.
Regado’s lead program, REG1, is comprised of two parenteral agents, the first being a potent and highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to completely or partially reverse the anticoagulant effect of RB006. Regado recently completed a phase 2a study of REG1 in percutaneous coronary intervention (PCI) and is planning the initiation of a rigorous phase 2b program in this same indication in 3Q2009.
More information can be found at http://www.regadobio.com.